{
    "2019-09-04": [
        [
            {
                "time": "2018-03-15",
                "original_text": "SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG",
                "features": {
                    "keywords": [
                        "SHAREHOLDER ALERT",
                        "Levi & Korsinsky",
                        "Investigation",
                        "Securities Fraud",
                        "Novartis AG"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Why Novartis (NVS) Stock Might be a Great Pick",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Stock",
                        "Great Pick"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-22",
                "original_text": "Novartis Inks Commercialization Deal for Tysabri Biosimilar",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Commercialization Deal",
                        "Tysabri Biosimilar"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-18",
                "original_text": "ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "features": {
                    "keywords": [
                        "ONGOING INVESTIGATION",
                        "Schall Law Firm",
                        "Claims",
                        "Novartis AG"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}